In VICTORIA, patients within the first 3 quartiles of peptide elevation had results more impressive than the overall findings. However, patients with the highest quartile did not seem to benefit. This raises the question whether the sickest of the sick patients will benefit from vericiguat, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
An interesting finding was that patients within the first 3 quartiles of peptide elevation actually had an even more impressive benefit in terms of the primary endpoint give or take about 20%, but [those with] the highest quartile of NT-proBNP did not seem to benefit. This raises the question whether the sickest of the sick patients perhaps are too sick to benefit from vericiguat, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi. Results for VICTORIA were presented Saturday at the 2020 American College of Cardiology / World Congress of Cardiology Virtual Experience.
Transcript
Did the results show any noteworthy differences by subgroup?
An interesting finding was that the first 3 quartiles of peptide elevation actually had an even more impressive benefit in terms of the primary endpoint give or take about 20% or so, but the highest quartile of NT-proBNP did not seem to benefit, which sort of raises the question whether the sickest of the sick patient, perhaps are too sick to benefit and if the therapy would have been only in a group of patients excluding the top quartile, the results will be even more impressive.
Now, we have to take this with caution. These are secondary analysis and whenever you do these secondary analyses, there's always a potential for a chance finding, but it really stands out that if you look at the quartertile 1, quartile 2, and quartile 3, you see substantial benefit. If anything, in the quartile 4 the point estimate goes in the opposite direction and you don't see any benefit. So, that's 1 subgroup that stands out.
These results focus on patients with heart failure with reduced ejection fraction. So, can we look forward to results for preserved ejection fraction?
There is a sister study that was also done in heart failure with preserved ejection fraction called the VITALITY study. It was not a morbidity, mortality study, but rather a study looking at quality-of-life and functional capacity. So, those results will be coming out I would assume shortly.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More